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Investigators of anion channels are frequently heard
bemoaning the absence of potent, speciﬁc inhibitors of
their favorite channel. The lack of such blockers has
been particularly frustrating for researchers investigating
the cystic ﬁbrosis transmembrane conductance regulator
(CFTR) Cl
 
 
 
 channel, which plays a central role in
electrolyte transport across epithelial tissues (Welsh et
al., 2001). Perhaps the complaints of CFTR researchers
might soon be a thing of the past following the discovery
of glycine hydrazides by Chatchai Muanprasat and
colleagues, which is reported in this issue of the 
 
Journal
of General Physiology
 
 (Muanprasat et al., 2004). In brief,
the authors employ a high-throughput screening (HTS)
assay for the identiﬁcation of CFTR inhibitors to dis-
cover glycine hydrazides and then investigate the ef-
fects of these agents on CFTR function in experiments
that range from single channels to animal models (Mu-
anprasat et al., 2004). In the process, Muanprasat and
colleagues ﬁnd that glycine hydrazides have a novel
mechanism of action: occlusion of the extracellular
end of the CFTR pore. All in all, the work is a tour de
force of CFTR pharmacology.
The pharmacology of the CFTR Cl
 
 
 
 channel has
attracted signiﬁcant interest in recent years. Much of
this attention has been fuelled by the search for rational
new therapies for diseases caused by CFTR malfunc-
tion. Mutations that, in general, abolish the function
of CFTR cause the life-threatening genetic disease
cystic ﬁbrosis (CF; Welsh et al., 2001). By contrast,
some forms of male infertility, disseminated bron-
chiectasis and chronic pancreatitis are caused by CFTR
mutations that are likely to preserve partial CFTR
function (Welsh et al., 2001). Other diseases, such as
secretory diarrhea and polycystic kidney disease involve
unphysiologic activation of the CFTR Cl
 
 
 
 channel
(Sullivan et al., 1998; Al-Awqati, 2002). Besides treat-
ments for disease and perhaps even male contraception,
CFTR inhibitors are important in several other respects:
(a) as probes to identify CFTR-dependent function
and to investigate CFTR structure and function, (b) to
study the pathogenesis of lung disease in CF, and (c)
to develop animal models with which to evaluate new
therapies for CF.
A wide spectrum of diverse small molecules, which
inhibit the CFTR Cl
 
 
 
 channel, has been identiﬁed.
Analysis of these molecules reveals several common
themes: they are anions, most are lipophilic, and many
are large in size. Moreover they inhibit CFTR by two
general mechanisms: open-channel and allosteric block
(Cai et al., 2002). A variety of large organic anions (e.g.,
glibenclamide) are open-channel blockers of the CFTR
Cl
 
 
 
 channel. These agents inhibit CFTR by binding
within the deep wide vestibule at the intracellular end
of the CFTR pore and preventing Cl
 
 
 
 ﬂow by occlud-
ing the permeation pathway (Fig. 1, A and B; Cai et
al., 2002). By contrast, elevated concentrations of
several agents that potentiate CFTR Cl
 
 
 
 currents (e.g.,
genistein) inhibit CFTR by an allosteric mechanism.
These agents inhibit CFTR by interacting with the
nucleotide-binding domains (NBDs), which control
channel gating, and slowing greatly the rate of channel
opening (Fig. 1, A and C; Cai et al., 2002). Because the
characteristics of CFTR inhibition by open-channel
and allosteric blockers differ, these agents can be dis-
tinguished by the effects of (a) voltage, (b) external
Cl
 
 
 
 concentration, and (c) the inorganic phosphate
analogue pyrophosphate (PP
 
i
 
) that disrupts ATP-depen-
dent gating. Inhibition of CFTR by open-channel
blockers is voltage dependent and enhanced when the
external Cl
 
 
 
 concentration is reduced, but unaffected
by PP
 
i
 
 (Cai et al., 2002). In contrast, inhibition of
CFTR by allosteric blockers is voltage independent and
unaffected by reducing the external Cl
 
 
 
 concentration,
but relieved by PP
 
i
 
 and elevated concentrations of ATP
(Cai et al., 2002).
Despite the plethora of CFTR inhibitors identiﬁed
using conventional assays of CFTR function, potency
and speciﬁcity have remained intractable problems.
Few agents have been identiﬁed that inhibit CFTR with
nanomolar afﬁnity. Worse, no speciﬁc blockers of the
CFTR Cl
 
 
 
 channel have been identiﬁed. Open-channel
 
Abbreviations used in this paper:
 
 ADPKD, autosomal dominant polycystic
kidney disease; CFTR, cystic fibrosis transmembrane conductance
regulator; FRT, Fischer rat thyroid; HTS, high-throughput screening;
NBD, nucleotide-binding domain. 
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blockers of CFTR invariably block other types of
Cl
 
 
 
 channels, whereas allosteric blockers interact with
other targets within cells at concentrations similar to
those that inhibit CFTR. The existence of so-called
pseudo-CFTR Cl
 
 
 
 channels of unknown molecular iden-
tity, but properties and regulation strikingly similar to
those of CFTR (Marvão et al., 1998), highlights both
the importance and difﬁculty of discovering speciﬁc
blockers of the CFTR Cl
 
 
 
 channel.
In recent years, there has been a revolution in drug
discovery. First, the determination of the atomic struc-
tures of proteins has facilitated greatly rational drug de-
sign. Second, HTS of compound libraries has acceler-
ated dramatically the discovery of lead compounds for
drug development. In the search for drugs to treat CF,
several groups have employed the latter strategy to
identify novel small molecules that either restore the
cell surface expression of mutant Cl
 
 
 
 channels (CFTR
correctors) or rescue their defective channel gat-
ing (CFTR potentiators). Using Fischer rat thyroid
(FRT) epithelial cells coexpressing recombinant human
CFTR and a green ﬂuorescent protein with ultra-high
Figure 1. Mechanism of action of
CFTR inhibitors. (A–D) Simpliﬁed
models of the CFTR Cl  channel and
the effects of open-channel and allo-
steric  blockers. Schematic representa-
tions of the I–V relationships of CFTR
Cl  currents in the absence (continuous
line) and presence (dotted line) of
blockers under conditions of symmetri-
cal Cl -rich solutions are shown beneath
each model. (A) The CFTR pore con-
tains a deep wide intracellular vestibule
and a shallow extracellular vestibule
separated by a selectivity ﬁlter (for
review see Cai et al., 2003). (B) Large
anions (A ; e.g., glibenclamide) inhibit
CFTR by occluding the intracellular
vestibule (Cai et al., 2002). (C) Allosteric
blockers (e.g., genistein) inhibit CFTR
by interfering with channel gating
(Wang et al., 1998; Cai et al., 2002).
Because the NBDs likely function as a
head-to-tail dimer (Vergani et al., 2003;
Lewis et al., 2004), allosteric blockers
might inhibit channel gating by pre-
venting dimer formation (Ai et al.,
2004). (D) The glycine hydrazide GlyH-
101 (A ) inhibits CFTR by occluding
the extracellular vestibule (Muanprasat
et al., 2004). MSD, membrane-span-
ning domain; R, regulatory domain; P,
phosphorylation. 
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halide sensitivity, Alan Verkman and his colleagues
have developed an automated HTS for small molecules
that potentiate the activity of wild-type and mutant
CFTR either by themselves or in synergy with cAMP ag-
onists (Yang et al., 2003). In this assay, CFTR potentia-
tors are identiﬁed as agents that strongly enhance the
time course of ﬂuorescence decrease and, hence, the
rate of iodide inﬂux into FRT cells, following chloride
replacement with iodide (Yang et al., 2003). This
screening strategy has proved so successful (e.g., Yang
et al., 2003) that the challenge for Verkman and his col-
leagues now is to carefully decide which of the many
CFTR potentiators that they have identiﬁed to pursue
further in their quest to develop new therapies for CF.
Concurrent with their search for CFTR potentiators,
Verkman and colleagues modiﬁed their HTS assay to
identify agents that interact directly with CFTR to in-
hibit CFTR-mediated iodide inﬂux. Their initial screen
of 50,000 compounds identiﬁed the thiazolidinone
CFTR
 
inh
 
-172, a CFTR inhibitor with several highly de-
sirable properties (Ma et al., 2002). First, potency:
CFTR
 
inh
 
-172 reversibly inhibited CFTR-mediated Cl
 
 
 
currents with a half maximal inhibitory concentration
(K
 
i
 
) of 
 
 
 
300 nM, an increase in potency of almost 500-
fold compared with the widely used CFTR blocker gli-
benclamide (Ma et al., 2002). Second, speciﬁcity: at rel-
evant concentrations, CFTR
 
inh
 
-172 was without effect on
several ion channels and transporters found in epithe-
lial tissues including Ca
 
2
 
 
 
-activated and volume-regu-
lated Cl
 
 
 
 channels and the ATP-binding cassette trans-
porter P-glycoprotein (Ma et al., 2002). Third, efﬁcacy:
CFTR
 
inh
 
-172 inhibited cholera toxin–induced ﬂuid se-
cretion in the small intestine of mice, dramatically
highlighting the therapeutic potential of CFTR block-
ers (Ma et al., 2002). CFTR
 
inh
 
-172, however, suffers two
drawbacks, that might constrain the drug’s usefulness:
ﬁrst, limited water solubility (
 
 
 
20 
 
 
 
M) and, second, re-
duced potency in intact cells and tissues (K
 
i
 
 
 
  
 
5 
 
 
 
M;
Muanprasat et al., 2004).
Aiming to do better, Verkman and his colleagues
screened another 100,000 small molecules selected for
their chemical diversity and drug-like properties. They
identiﬁed four compounds that are potent inhibitors of
CFTR-mediated iodide inﬂux (K
 
i
 
 
 
  
 
5 
 
 
 
M; Muanprasat
et al., 2004). For two reasons, the glycine hydrazides
were particularly attractive for further study. First, many
glycine hydrazides can inhibit CFTR-mediated iodide
inﬂux (Muanprasat et al., 2004). Second, 
 
N
 
-(2-naph-
thalenyl)-([3,5-dibromo-2,4-dihydroxyphenyl]methyl-
ene)glycine hydrazide (GlyH-101) inhibition of CFTR-
mediated iodide inﬂux was rapid in onset, readily re-
versible, and effective after CFTR activation by agonists
that act by both direct and indirect mechanisms
(Muanprasat et al., 2004). Encouraged by these results,
which indicate that glycine hydrazides are amenable to
chemical modiﬁcation and suggest that these agents
might act from the extracellular side of the membrane,
the authors embarked on an exhaustive characteriza-
tion of glycine hydrazides and their effects on the
CFTR Cl
 
 
 
 channel.
To investigate the relationship between the chemical
structure of glycine hydrazides and CFTR inhibition,
the authors modiﬁed systematically the structure of
GlyH-101 and assessed CFTR function in FRT epithelia.
These experiments demonstrate that 
 
N
 
-(2-naphthalenyl)
and 3,5-dibromo-2,4-dihydroxyphenyl substituents in gly-
cine hydrazides are required for maximal inhibition of
the CFTR Cl
 
 
 
 channel. The authors also examined the
physical properties of glycine hydrazides. In contrast to
CFTR
 
inh
 
-172, GlyH-101 is highly water-soluble (
 
 
 
1 mM),
and between pH 6.0 and 8.0 it is a monovalent anion
(Muanprasat et al., 2004).
To investigate how GlyH-101 inhibits CFTR, the au-
thors studied whole-cell and single-channel CFTR Cl
 
 
 
currents in FRT cells expressing recombinant wild-type
human CFTR using the patch-clamp technique. GlyH-
101 caused a voltage-dependent block of whole-cell
CFTR Cl
 
 
 
 currents with the potency of CFTR inhibi-
tion inﬂuenced by the extracellular Cl
 
 
 
 concentration
(Muanprasat et al., 2004). Visual inspection of single-
channel records indicates that CFTR inhibition by
GlyH-101 was characterized by numerous drug-induced
closures interrupting channel openings, with the drug
dramatically decreasing mean channel open-time with-
out altering single-channel current amplitude (Muan-
prasat et al., 2004). These characteristics of GlyH-101
inhibition of CFTR are unexceptional; they suggest
that GlyH-101 is an open-channel blocker of CFTR that
inhibits the channel with “intermediate” speed (Hille,
2001).
The characteristic of channel block that sets GlyH-
101 apart from other open-channel blockers of CFTR is
the shape of the current–voltage (I–V) relationship.
Typically, open-channel blockers of CFTR cause out-
ward rectiﬁcation of CFTR Cl
 
 
 
 currents, indicating that
Cl
 
 
 
 ﬂow from the intra- to the extracellular side of the
membrane is more strongly attenuated than that in the
opposite direction. In contrast, submaximal concentra-
tions of GlyH-101 (
 
 
 
30 
 
 
 
M) caused inward rectiﬁca-
tion of CFTR Cl
 
 
 
 currents, indicating that Cl
 
 
 
 ﬂow
from the extra- to the intracellular side of the mem-
brane is more strongly attenuated than that in the op-
posite direction (Muanprasat et al., 2004). Taken to-
gether, the simplest interpretation of the data is that
positive voltages drive the negatively charged GlyH-101
into the extracellular vestibule of the CFTR pore where
it binds and occludes Cl
 
 
 
 permeation (Fig. 1 D). Chan-
nel block is relieved both by negative voltages and re-
ducing the extracellular Cl
 
 
 
 concentration; these ma-
neuvers enable Cl
 
 
 
 ﬂow from the intracellular to the 
112
 
CFTR Channel Pharmacology
 
extracellular side of the membrane to ﬂush GlyH-101
from its binding site within the extracellular vestibule.
Not content to elucidate the molecular mechanism
of CFTR inhibition by GlyH-101, the authors investi-
gated the efﬁcacy with which GlyH-101 inhibits CFTR
function in respiratory and intestinal epithelia at both
the intact tissue and whole animal levels. GlyH-101
(10–50 
 
 
 
M) completely abolished cAMP-stimulated short-
circuit current, a measure of CFTR-mediated trans-
epithelial electrolyte transport, in respiratory and intes-
tinal epithelia from humans and mice (Muanprasat et
al., 2004). Consistent with these data, topical applica-
tion of GlyH-101 (10 
 
 
 
M) to nasal epithelia of mice
rapidly attenuated CFTR function in vivo (Muanprasat
et al., 2004). Finally, like CFTR
 
inh
 
-172, GlyH-101 dra-
matically inhibited cholera toxin–induced ﬂuid secre-
tion in the small intestine of mice (Muanprasat et al.,
2004). However, in contrast to CFTR
 
inh
 
-172, which must
be administered intraperitoneally, GlyH-101 was active
when added directly into the lumen of the small intes-
tine (Muanprasat et al., 2004). Taken together, the data
suggest that glycine hydrazides have great promise as
blockers of the CFTR Cl
 
 
 
 channel.
What of the future? One pressing question and sev-
eral exciting possibilities are suggested by the present
work. First, the pressing question: speciﬁcity. GlyH-101
was without effect on P-glycoprotein and non-CFTR–
mediated Cl
 
 
 
 currents in murine nasal epithelia and
only inhibited Ca
 
2
 
 
 
-activated Cl
 
 
 
 channels at elevated
concentrations (Muanprasat et al., 2004). While these
initial data are encouraging, it will be important to test
the effects of glycine hydrazides on a battery of targets,
including ion channels and ATP-binding cassette trans-
porters commonly found in epithelial tissues.
Second, the architecture of the CFTR pore. To date,
studies using permeant anions, especially those that
bind tightly within the CFTR pore (e.g., Au(CN)
 
2
 
 
 
;
Gong and Linsdell, 2003), have proved most informa-
tive. Work by Smith et al. (2001) and Gong and Lins-
dell (2003) indicate that arginine (R) 334, a positively
charged residue located toward the extracellular end of
the sixth transmembrane segment, plays a crucial role
in anion permeation through the CFTR pore by con-
centrating anions within the extracellular vestibule.
However, the identity of other residues that line the ex-
ternal mouth of the CFTR pore is poorly understood.
The suggestion that GlyH-101 binds at the external
mouth of the CFTR pore to inhibit Cl
 
 
 
 ﬂow (Muanpra-
sat et al., 2004) raises the possibility that GlyH-101
might be a valuable probe of the extracellular vestibule
of the CFTR pore. In addition, GlyH-101 might be used
to investigate the regulation of CFTR function by exter-
nal Cl
 
 
 
 concentration (Wright et al., 2002).
Third, large animal models of CF. The failure of CF
mice to replicate the lung disease and pancreatic de-
struction characteristic of CF has prompted a search
for alternative animal models. Anatomical, biochemi-
cal, and functional data suggest that sheep lungs might
prove an excellent model for therapy evaluation (Har-
ris, 1997). The generation of cloned sheep argues that
a CF sheep might be produced using cloning technol-
ogy. However, the development of speciﬁc high-afﬁnity
inhibitors of the CFTR Cl
 
 
 
 channel raises the possibil-
ity that a pharmacological approach might prove suc-
cessful. Consistent with this idea, CFTR
 
inh
 
-172 pro-
duced viscous ﬂuid secretions from submucosal glands
of normal human and porcine airways reminiscent of
those of CF airways (Thiagarajah et al., 2004). Pharma-
cological inhibition of CFTR function in sheep lungs
might provide fresh insight into the pathogenesis of CF
lung disease. Moreover, agents like GlyH-101 might be
employed to investigate the physiological role of CFTR.
There is increasing recognition that CFTR is expressed
in a diverse variety of cells and tissues outside of epithe-
lia. Understanding the functions of CFTR in these tis-
sues is crucial for the development of effective thera-
pies for CF and related diseases.
Fourth, disease therapy. Secretory diarrhea is the
leading cause of death in young children worldwide
(Al-Awqati, 2002). The disease results from the irrevers-
ible activation of ﬂuid and electrolyte secretion in the
intestine (Al-Awqati, 2002). Ever since CFTR was identi-
ﬁed as the apical membrane Cl
 
 
 
 channel responsible
for cAMP-stimulated Cl
 
 
 
 secretion in intestinal epithe-
lia, there has been speculation that CFTR blockers
might be of value in the treatment of secretory diar-
rhea. However, it was not until the discovery of CFTR
 
inh
 
-
172 that proof of principle for this idea was obtained
(Ma et al., 2002). Based on the efﬁcacy with which in-
traluminal GlyH-101 inhibited intestinal ﬂuid secretion
in a mouse model of cholera, Muanprasat et al. (2004)
speculate that glycine hydrazides might be devel-
oped into a nonabsorbable drug therapy for secretory
diarrhea.
Inappropriate CFTR-driven ﬂuid accumulation also
contributes to the pathogenesis of autosomal dominant
polycystic kidney disease (ADPKD), the most common
single gene disorder to affect the kidney (Sullivan et al.,
1998). Because CFTR is located on the lumen-facing
membrane of epithelial cysts, there has been specula-
tion that it is not a suitable target for ADPKD therapy.
However, CFTR blockers, including CFTR
 
inh
 
-172, re-
tard cyst formation and enlargement (Hanaoka and
Guggino, 2000; Li et al., 2004), raising the possibility
that therapeutically active CFTR blockers might be of
value in the treatment of ADPKD.
Finally, what are the prospects for the rational design
of drugs based on the atomic structure of CFTR? Excit-
ingly, Hal Lewis and his colleagues at Structural Geno-
miX Inc. have recently determined the crystal structure 
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of NBD1 from murine CFTR (Lewis et al., 2004). How-
ever, the complexities of CFTR channel regulation
(e.g., Vergani et al., 2003) argue that the structure of
the complete protein will be required at atomic resolu-
tion for rational drug design. The successes of re-
searchers investigating CLC channels (e.g., Estévez et
al., 2003) should galvanize CFTR investigators to try
harder.
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